Cat Feline Infectious Peritonitis - Welfare Breakthrough

Feline Infectious Peritonitis was previously a fatal diagnosis for cats, but new antiviral treatments using GS-441524 have transformed FIP from a death sentence into a treatable disease with high survival rates.

Key Facts

FIP is caused by a mutation of feline coronavirus and was previously almost universally fatal within weeks of diagnosis
GS-441524 antiviral treatment achieves over 85% survival rates in cats completing the full treatment course
Treatment requires 84 days of daily injections or oral medication with regular monitoring
The drug was approved for veterinary use in Australia in 2021 and is increasingly available in other countries
Without approved supply chains, cats have died waiting for access to black market versions of the treatment

Welfare Considerations

The development of effective FIP treatment represents one of the most significant advances in companion animal welfare in recent years. Prior to antiviral treatment, a FIP diagnosis meant certain death within weeks, with cats experiencing progressive fluid accumulation, neurological symptoms, and severe suffering before dying or being euthanized. High survival rates with complete treatment courses mean that FIP-diagnosed cats can now expect full recovery and normal lifespan. Access to treatment remains a welfare concern where regulatory approval is pending or costs are prohibitive.

What You Can Do

Ensure your vet is aware of current FIP treatment options if your cat is diagnosed
Support regulatory approval processes for GS-441524 in your country to ensure safe supply
Donate to FIP research and access organizations helping cat owners afford treatment
Connect with the FIP Warriors support network for guidance on treatment access
Advocate for transparent pricing and fair access to life-saving veterinary medications